209 related articles for article (PubMed ID: 37099048)
1. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach.
Ipinloju N; Ibrahim A; da Costa RA; Adigun TB; Olubode SO; Abayomi KJ; Aiyelabegan AO; Esan TO; Muhammad SA; Oyeneyin OE
J Mol Model; 2023 Apr; 29(5):159. PubMed ID: 37099048
[TBL] [Abstract][Full Text] [Related]
2. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
3. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract][Full Text] [Related]
4. Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents.
Soliman AM; Ghorab MM
Bioorg Chem; 2019 Jul; 88():102956. PubMed ID: 31054432
[TBL] [Abstract][Full Text] [Related]
5. In-silico method for elucidation of prodigiosin as PARP-1 inhibitor a prime target of Triple-negative breast cancer.
Sundararajan P; Dharmaraj Rajaselvi D; Vivekananthan S; Priya Ramasamy S
Bioorg Chem; 2023 Sep; 138():106618. PubMed ID: 37244231
[TBL] [Abstract][Full Text] [Related]
6. Quantum chemical insight into molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-19 molecule 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(4-fluorophenyl)acetamide - dimer.
Mary SJJ; Siddique MUM; Pradhan S; Jayaprakash V; James C
Spectrochim Acta A Mol Biomol Spectrosc; 2021 Jan; 244():118825. PubMed ID: 32866803
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the New Inhibitors by Sulfadiazine and Modified Derivatives of α-D-glucopyranoside for White Spot Syndrome Virus Disease of Shrimp by In Silico: Quantum Calculations, Molecular Docking, ADMET and Molecular Dynamics Study.
Kumer A; Chakma U; Rana MM; Chandro A; Akash S; Elseehy MM; Albogami S; El-Shehawi AM
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744817
[TBL] [Abstract][Full Text] [Related]
8. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
9. Computational investigation of
Yousaf MA; Anwer SA; Basheera S; Sivanandan S
J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
[TBL] [Abstract][Full Text] [Related]
10. Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2.
Varma DA; Singh M; Wakode S; Dinesh NE; Vinaik S; Asthana S; Tiwari M
J Biomol Struct Dyn; 2023 Apr; 41(7):2956-2970. PubMed ID: 35196966
[TBL] [Abstract][Full Text] [Related]
11. Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor.
Chatterjee P; Karn R; Emerson IA; Banerjee S
Mol Biotechnol; 2024 Apr; 66(4):718-736. PubMed ID: 36732462
[TBL] [Abstract][Full Text] [Related]
12. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
14. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
15. Anti-parasitic drug discovery against
Akash S; Hosen ME; Mahmood S; Supti SJ; Kumer A; Sultana S; Jannat S; Bayıl I; Nafidi HA; Jardan YAB; Mekonnen AB; Bourhia M
Front Cell Infect Microbiol; 2023; 13():1222913. PubMed ID: 37662005
[TBL] [Abstract][Full Text] [Related]
16. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
Saini N; Grewal AS; Lather V; Gahlawat SK
Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
[TBL] [Abstract][Full Text] [Related]
17. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
18. In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.
Gnanaraj C; Sekar M; Fuloria S; Swain SS; Gan SH; Chidambaram K; Rani NNIM; Balan T; Stephenie S; Lum PT; Jeyabalan S; Begum MY; Chandramohan V; Thangavelu L; Subramaniyan V; Fuloria NK
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566187
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
[TBL] [Abstract][Full Text] [Related]
20. Screening of phytochemicals from
Yasmeen N; Ahmad Chaudhary A; K Niraj RR; Lakhawat SS; Sharma PK; Kumar V
J Biomol Struct Dyn; 2023 Dec; ():1-43. PubMed ID: 38141177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
